Lovells builds life sciences with Merck legal director

Sign in or register to continue reading.

Gain access to the latest news from The Lawyer.com, our jobs board, career insight and much more.

Register now to The Lawyer to access our latest news stories, read selected briefings from key firms and gain essential careers insight to help you make the most of your current and future roles.

Contact Us: if you have any questions regarding your subscription, call us on +44 (0)20 7292 3716 or email us at customerservices@thelawyer.com

Register now

Having problems?

Contact us on +44 (0)20 7292 3716 | email: customerservices@thelawyer.com

If you are looking for our Jobs site, please click here 

Latest Briefings

Canada: new occupational health and safety act expands scope of employer duties

On June 1, 2018, amendments to Alberta’s Occupational Health and Safety Act came into force, significantly expanding the nature of the health and safety obligations owed by employers and businesses in Alberta. This article focuses on one of the areas in which changes have been made: the expansion of the types of entities that have […]

Use of injunction in modern trespass cases

By Leanne Norton and Lucy Shepherd In two recent cases of trespass, injunctions have been the preferred remedy rather than possession. An injunction is a court order that requires a party to do a specific act, or to refrain from doing a specific act. Injunctions are a discretionary remedy and an interim injunction might be […]

Adjudication watch June 2018: what you need to know

In this latest ‘Adjudication Watch’ our construction team provides updates on significant adjudication decisions: Mailbox (Birmingham) Ltd v Galliford Try Building Ltd (formerly known as Galliford Try Construction Ltd) [2017] Christopher Linnett Ltd and Mr Christopher Linnett v Matthew J Harding [2017] Baldwin and another v J R Pickstock Ltd [2017] Victory House General Partner […]

Messi scores important victory in longrunning EU trademark dispute

The General Court of the European Union ruled that the Barcelona and Argentina football star Lionel Andrés Messi, can register his European Union trade mark (EUTM) application for ‘MESSI’ in classes 3, 9, 14, 16, 25 and 28 (covering a wide range of products including fragrances, jewellery, clothing and sports equipment) notwithstanding an opposition led […]

Recommended

White & Case partner snub sees Bracewell stall in London

Bracewell & Giuliani’s triumphant entry into the London market has stalled after it was snubbed by White & Case capital markets partner Peter Epp, who had been earmarked to launch the firm in the UK capital. Epp, who was meant to bring a team of lawyers with him, declined the opportunity at the firm of […]

Bircham ditches PQE for merit-based system

Bircham Dyson Bell has discarded the traditional use of PQE as the key component in grading solicitors. The firm has replaced it with a new performance-based structure, the Career Development Framework (CDF). HR director Richard Walden said that the PQE system is “outdated and fails to recognise the quality of work delivered”. The CDF establishes […]

Duo sets up Russian-focused JV in City

Jailed Russian oil baron Mikhail Khodorkovsky’s lawyer, Genrikh Padva, has launched a joint venture in London. The Moscow-based commercial and criminal litigator has set up the joint venture with London-based Katerina Haslam-Jones (née Sorokina), a former Norton Rose associate, who has advised Russian clients as a sole practitioner since 2002. Padva Haslam Jones & Partners […]

Taylor Wessing sees growth across all sectors

Taylor Wessing has posted a UK turnover increase of 14.3 per cent for 2006-07, with the firm registering double-digit growth across all three of its core jurisdictions. UK revenue hit £87.6m, while the firm’s German and French operations both posted 20 per cent revenue increases. Taylor Wessing UK managing partner Michael Frawley said the firm’s […]

Fasken handed cancer drug licensing deal

Fasken Martineau Stringer Saul has represented longstanding client Antisoma on a global licensing agreement with pharmaceutical firm Novartis. The deal concerns Antisoma’s vascular disruption drug AS1404, which is in development for the treatment of lung, ovarian and prostate cancers. If all requirements are met Antisoma could receive up to $890m (£446.91m) in addition to royalties […]

Register now to The Lawyer to access our latest news stories, read selected briefings from key firms and gain essential careers insight to help you make the most of your current and future roles.

Contact Us: if you have any questions regarding your subscription, call us on +44 (0)20 7292 3716 or email us at customerservices@thelawyer.com

Register now

Having problems?

Contact us on +44 (0)20 7292 3716 | email: customerservices@thelawyer.com

If you are looking for our Jobs site, please click here